GEN Exclusives

More »

GEN News Highlights

More »
Sep 24, 2012

Heart Failure Drug Reduces Mortality at Phase III

  • Novartis’ recombinant human relaxin-2 drug candidate RLX030 (serelaxin) reduced all-cause mortality in a placebo-controlled Phase III study involving 1,161 patients with heart failure, and met one of its two dyspnea reduction primary endpoints. The Relax-AHF trial used two different scales to measure reductions in dyspnea, and one of these was met, but the other didn’t reach statistical significance.

    The study involved administering RLX030 to patients on admission to hospital in the form of an intravenous infusion for up to 48 hours, in addition to standard of care therapy involving loop diuretics. Novartis says it plans to discuss the trial results with regulatory authorities worldwide, and will present the data at the American Heart Association congress in Los Angeles next month. 


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?